Login to Your Account


LONDON – Cellact Pharma GmbH has sealed a $250 million plus royalties deal with Mundipharma International Ltd. for its phase II anticancer prodrug, Cap7.1.

LONDON – E-therapeutics plc has completed a corporate reformulation, cutting four of six in-house preclinical projects and now aiming to find partners for candidates generated by its pioneering systems biology drug discovery platform.

LONDON - The U.K. government has given the industry formal notice that it aims to keep the Medicines and Healthcare products Regulatory Agency (MHRA) involved in and aligned with the EMA when the U.K. leaves the EU.

More EUROPE Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: